Open Trial of Injectable Risperidone for Methamphetamine Dependence

Journal of Addiction Medicine

Volumn 3, Issue 2, 2009, Pages 55-65

  Meredith, Charles W ^a,b,c   Jaffe, Craig ^a,b   Cherrier, Monique ^a,b   Robinson, Joseph P ^a   Malte, Carol A ^a   Yanasak, Elisia V ^a   Kennedy, Annette ^a   Ferguson, Laura C ^a,b   Tapp, Andre M ^a,b   Saxon, Andrew J ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Addiction severity; Injection; Methamphetamine; Neuropsychological function; Psychiatric symptoms; Risperidone

Indexed keywords

EID: 70349254294     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31818e2185     Document Type: Article

References (63)

1. United Nations Office on Drugs and Crime. World Drug Report 2007. Available at http://www.unodc.org/pdf/research/wdr07/WDR-2007.pdf.
2. United Nations Office on Drugs and Crime. World Drug Report 2000. New York: Oxford University Press; 2000.
3. Rawson RA, Marinelli-Casey P, Anglin MD, et al. A multi-site comparison of psychosocial approaches for the treatment of methamphet- amine dependence. Addiction. 2004;99:708-717.
4. Galloway GP, Newmeyer J, Knapp T, et al. Imipramine for the treatment of cocaine and methamphetamine dependence. J Addict Dis. 1994;13: 201-216.
5. Galloway GP, Newmeyer J, Knapp T, et al. A controlled trial of imipramine for the treatment of methamphetamine dependence. JSubst Abuse Treat. 1996;13:493-497.
6. Shoptaw S, Rawson RA, McCann MJ, et al. The matrix model of outpatient stimulant abuse treatment: evidence of efficacy. J Addict Dis. 1994;13:129-141.
7. Batki S, Moon J, Bradley M, et al. Fluoxetine and methamphetamine dependence-a controlled trial: preliminary analysis. NIDA Res Monogr. 1999;180:235.
8. Shoptaw S, Huber A, Peck J, et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of metham- phetamine dependence. Drug Alcohol Depend. 2006;85:12-18.
9. Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacol- ogy. 2007;33:1162-1170.
10. Johnson BA, Ait-Daoud N, Elkashef AM, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int J Neuropsychopharmacol. 2007;11:1-14.
11. Heinzerling KG, Shoptaw S, Peck JA, et al. Randomized, placebo- controlled trial of baclofen and gabapentin for the treatment of meth- amphetamine dependence. Drug Alcohol Depend. 2006;85:177-184.
12. Tiihonen J, Kuoppasalmi K, Fohr J, et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am JPsy- chiatty. 2007;164:160-162.
13. Wickes W, Longo M, White J. Randomized controlled trial of damphetamine maintenance for treatment of methamphetamine dependence [abstract]. Eighth International Society of Addiction Medicine Annual Meeting, Oporto, Portugal, 2006.
14. Urschel HC III, Hanselka LL, Gromov I, et al. Open-label study of a proprietary treatment program targeting type A gamma-aminobutyric acid receptor dysregulation in methamphetamine dependence. Mayo Clin Proc. 2007;82:1170-1178.
15. Brodie JD, Figueroa E, Laska EM, et al. Safety and efficacy of gamma- vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse. 2005;55:122-125.
16. Arnt J. Sertindole and several antipsychotic drugs differentially inhibit the discriminative stimulus effects of amphetamine, LSD and St 587 in rats. Behav Pharmacol. 1992;3:11-18.
17. Arnt J. Inhibitory effects on the discriminative stimulus properties of D-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system? Psychopharmacology (Berl). 1996;124:117-125.
18. Rush CR, Stoops WW, Hays LR, et al. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Phar- macol Exp Ther. 2003;306:195-204.
19. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:1018-1028. (Pubitemid 34586949)
20. Weickert TW, Goldberg TE, Marenco S, et al. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology. 2003;28:1491-1500.
21. Simon SL, Domier C, Carnell J, et al. Cognitive impairment in individuals currently using methamphetamine. Am J Addict. 2000;9:222-231.
22. Simon SL, Domier CP, Sim T, et al. Cognitive performance of current methamphetamine and cocaine abusers. JAddict Dis. 2002;21:61-74.
23. Jaffe C, Bush KR, Straits-Troster K, et al. A comparison of metham-phetamine-dependent inpatients with and without childhood attention deficit hyperactivity disorder symptomatology. J Add Dis. 2005;24:133-152.
24. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphet- amine abusers. Am J Psychiatry. 2001;158:377-382
25. Nagai T, Takuma K, Dohniwa M, et al. Repeated methamphetamine treatment impairs spatial working memory in rats: reversal by clozapine but not haloperidol. Psychopharmacology (Berl). 2007;194:21-32.
26. Meredith CW, Jaffe C, Yanasak E, et al. An open-label pilot study of risperidone in the treatment of methamphetamine dependence. J Psychoactive Drugs. 2007;39:167-172.
27. Simon SL, Dacey J, Glynn S, et al. The effect of relapse on cognition in abstinent methamphetamine abusers. JSubst Abuse Treat. 2004;27:59-66.
28. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. JClin Psychiatry. 1999;60(Suppl 10):5-14.
29. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(Suppl 19):6-12.
30. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharma- cology. 1998;18:63-101.
31. Meneses A. 5-HT system and cognition. Neurosci Biobehav Rev. 1999; 23:1111-1125.
32. Preskom SH. Classification of neuropsychiatric medications by principle mechanism of action: a meaningful way to anticipate pharmacodynamically mediated drug interactions. JPsychiatr Pract. 2003;9:376-383.
33. Vanderschuren LJ, Beemster P, Schoffelmeer AN. On the role of noradrenaline in psychostimulant-induced psychomotor activity and sensitization. Psychopharmacology (Berl). 2003;169:176-185.
34. Bohus B, Koolhaas JM, Korte SM, et al. Forebrain pathways and their behavioural interactions with neuroendocrine and cardiovascular function in the rat. Clin Exp Pharmacol Physiol. 1996;23:177-182.
35. Childress AR, Mozley PD, McElgin W, et al. Limbic activation during cue-induced cocaine craving. Am J Psychiatry. 1999;156:11-18.
36. Koob GF. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry. 1999;46:1167-1180.
37. Weiss F, Ciccocioppo R, Parsons LH, et al. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci. 2001;937:1-26.
38. Zhang XY, Kosten TA. Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. Biol Psychiatry. 2005;57:1202-1204.
39. Marder SR. Overview of partial compliance. J Clin Psychiatry. 2003;64 (Suppl 16):3-9.
40. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. JClin Psychiatry. 2003;64(Suppl 16):14-17.
41. Pettinati HM, Volpicelli JR, Pierce JD Jr, et al. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis. 2000;19:71-83.
42. Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry. 1997;54:737-742.
43. McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J erv Ment Dis. 1980;168:26-33.
44. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med. 1983;13:595-605.
45. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS):recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24:97-99.
46. Barnes TR. A rating scale for drug-induced akathisia. Br JPsychiatry. 1989;154:672-676.
47. Barnes TR. The Barnes Akathisia Rating Scale-revisited. JPsychopharmacol. 2003;17:365-370.
48. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
49. Branch PR. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU assessment manual for psychopharmacology. Revised DHEW Pub No (ADM) ed. Rockville: National Institute of Mental Health; 1976:534-537.
50. Wilkinson GS. The Wide Range Achievement Test. 3rd ed. Wilmington, DE: Wide Range, Inc.; 1993.
51. Golden JC. Stroop Color and Word Test. Chicago, IL: Stoelting Company; 1978.
52. Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia. 1967;5:135-140.
53. Barr A, Brandt J. Word-list generation deficits in dementia. J Clin Exp Neuropsychol. 1996;18:810-822.
54. Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed. San Antonio, TX: The Psychological Corporation; 1997.
55. Weschler D. Wechsler Memory Scale. 3rd ed. San Antonio, TX: The Psychological Corporation; 1997.
56. Benedict RH, Schretlen D, Groninger L, et al. Hopkins Verbal Learning Test-Revised: normative data analysis of inter-form and test-retest reliability. Clin Neuropsychologist. 1998;12:43-55.
57. Benedict RH. Brief Visual Memory Test-revised. Odessa, Florida: Psychological Assessment Resources, Inc; 1997.
58. Kløive H. Grooved Pegboard. Lafayette, IN: Lafayette Instruments;1963.
59. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharma-codynamics. J Clin Psychiatry. 2003;64(Suppl 16):18-23.
60. Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther. 2004;26:1994-2002.
61. Carroll KM. A cognitive-behavioral approach: treating cocaine addiction. Therapy manuals for drug addiction. Rockville, MD: National Institute on Drug Abuse; 1998.
62. Stuber GD, Roitman MF, Phillips PE, et al. Rapid dopamine signaling in the nucleus accumbens during contingent and noncontingent cocaine administration. Neuropsychopharmacology. 2005;30:853-863.
63. Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006;163:396-401.